FDA presses 2,200+ companies to fix missing clinical trial results

Move amid evidence of widespread reporting gaps

Orchid Pharma submits Q4 FY26 SEBI compliance certificate to NSE, BSE

Routine regulatory filing confirms completion of demat and share transfer compliances for March quarter

Mumbai’s Apex Hospital achieves landmark 607 knee replacement surgeries in FY26

The event also featured discussions on emerging trends in joint replacement surgery

Apollo Hospitals Chennai performs India’s first adaptive deep brain stimulation for Parkinson’s

Milestone marks a major leap toward real-time, personalised neuromodulation therapy as India’s Parkinson’s burden rises sharply

Chiba University study flags allergy risk in high-binding antibody drugs

For the biopharma industry, the study strengthens the case for balancing immune-cell engagement with tolerability in antibody discovery platforms

GSK Pharma shareholders back Ronojit Biswas’ Board, CFO appointment via postal ballot

Both ordinary resolutions sail through with over 99.6% votes in favour, strengthening leadership continuity at the drugmaker

Dabur reports steady domestic growth amid global headwinds in Q4 FY26

The India FMCG business showed a sequential recovery and is expected to post high-single digit growth

ImmunityBio responds to FDA concerns over promotional content

Aurobindo gets USFDA approval for Dapagliflozin with 180-day exclusivity

Immediate U.S. launch planned for Farxiga®-equivalent diabetes drug; opportunity pegged at $10.2 billion in annual market size

Aurobindo Pharma wins USFDA approval for generic Xigduo XR

Immediate U.S. launch planned for dapagliflozin-metformin ER tablets; addressable market estimated at $514 millionannually